{
    "medicine_id": "e5855aee4a4b0b05107119920625a362a0ff1c51",
    "platform_id": "DB05222",
    "metadata": {
        "name": "Eucrisa 20 mg 1g Ointment",
        "composition": "20 mg 1g KB001",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of infections caused by multi drug resistant em Pseudomonas aeruginosa em",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "KaloBios is developing KB001 a PEGylated engineered human Fab fragment for the prevention and treatment of em Pseudomonas aeruginosa em infections The Fab fragment is specific for the PcrV antigen an essential component of the Type III secretion system a key virulence factor with multiple roles in both infection and pathogenesis KB001 shows potent activity in mouse models of pulmonary infection reducing mortality and leading to effective clearance of bacteria from infected lungs This molecule therefore represents an attractive candidate for clinical evaluation in the prevention or treatment of em Pseudomonas em infection in Cystic Fibrosis pneumonia and other indications",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}